Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer

Fig. 3

The results of HCT-1165FR cells treated with THLG-EXO/5-FU/miR-21i in vitro. a Real-time fluorescent quantitative PCR analysis of relative expression change of miR-21 level in HCT-1165FR cells treated with THLG-EXO/5-FU/miR-21i, THLG-EXO or miR-21i. Data were expressed as mean ± SD. n = 3. b Western blot analysis of hMSH2 and PTEN protein levels of HCT-1165FR cells treated with THLG-EXO/5-FU/miR-21i. c Flow cytometric analysis of AnnexinV-FITC/PI stained HCT-1165FR cells treated with THLG-EXO, THLG-EXO/miR-21i, THLG-EXO/5-FU or THLG/5-FU/miR-21i. d Cell cycle profiles of HCT-1165FR cells after treatment as described in c; e the proliferation of HCT-1165FR cells after treatment as described in c. Data were expressed as means ± SD. n = 5;*: significantly different from other groups (p < 0.05), **: extremely significantly different from other groups (p < 0.01)

Back to article page